Yuansi Biotech completed a $150 million Series B financing.

36Kr learned that "YuanSi Bio" announced the completion of a $150 million Series B financing round. The round was led by an international biotech fund, co-led by Decheng Capital and CDH VGC, with participation from a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Temasek's independently wholly-owned subsidiary Temasek Brightsight Capital, Qiming Venture Partners, Boyuan Capital, and well-known industrial investment institutions. Meanwhile, existing shareholders such as AstraZeneca, Lilly Asia Ventures, Sinovation Ventures, Matrix Partners China, GL Ventures, Biotech Development Fund, and Legend Capital continued to increase their stakes. The funds will be primarily used to deepen the intelligent iteration of its self-developed macrocyclic peptide discovery platform Synova™ and accelerate the transformation of the company's diversified innovative drug pipeline into the clinical stage.